ISID Home
about ISID | membership | programs | publications | resources | 14th ICID | site map
 
ProMed Home
 
  Navigation
Home
Subscribe/Unsubscribe
Search Archives
Announcements
Recalls/Alerts
Calendar of Events
Maps of Outbreaks
Submit Info
FAQs
Who's Who
Awards
Citing ProMED-mail
Links
Donations
About ProMED-mail
 
Archive Number 20090617.2237
Published Date 17-JUN-2009
Subject PRO/ERR> Influenza A (H1N1) - worldwide (65): antivirals in pregnancy, corr
INFLUENZA A (H1N1) - WORLDWIDE (65): ANTIVIRALS IN PREGNANCY, CORRECTION
************************************************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Wed 17 Jun 2009
From: Nicholas Bennett <bennetni@upstate.edu>


Re: ProMED-mail Influenza A (H1N1) - worldwide (65): antivirals in 
pregnancy 20090616.2224
----------------------------------------------------------------------
In the recent update of the safety of using Tamiflu during pregnancy, 
I spotted an error. It was incorrectly stated that Tamiflu and 
Relenza were oral and intranasal formulations of oseltamivir 
respectively. In fact, Relenza is an inhaled (but not intranasal) 
formulation of zanamivir -- an entirely different neuraminidase 
inhibitor.

The distinction is important on 2 counts: Relenza is difficult to 
administer to small children and to very sick patients who are 
intubated, as it requires the patient inhale the drug. Also, the 
2008-2009 seasonal H1N1 influenza (not the H1N1 swine-origin 
influenza) has been nearly 100 percent resistant to oseltamivir in 
the United States, but sensitive to zanamivir.

In the approaching winter season, this will pose issues with 
treatment -- both empiric and targeted. H1N1 (human) will likely 
require amantadine or zanamivir treatment, whereas H1N1 (swine 
origin) will hopefully remain susceptible to oseltamivir, and 
influenza B is inherently resistant to amantadine so will require 
oseltamivir or zanamivir. H3N2 has been resistant to amantadine in 
the recent past as well. The only common drug is zanamivir, so for 
empiric treatment of young children or very sick patients, 
combination therapy will likely be the only feasible approach. This 
was the recommendation for the 2008-2009 season, but will have 
ramifications for drug supply in the event of a widespread epidemic 
with potentially limited vaccine control.

Rapid diagnostics will help with narrowing drug coverage but are not 
available in many locations and even multiplex PCR can take several 
days.

--
Nicholas Bennett MA(Cantab), PhD, MB/BChir
Fellow in Pediatric Infectious Disease
Department of Pediatrics
SUNY Upstate Medical University
750 East Adams Street
Syracuse 13210
USA
<bennetni@upstate.edu>

[ProMED-mail thanks Nicholas Bennett and also Stephen D Shafran 
(University of Alberta) and others who have pointed out the error in 
a Moderator's comment that Tamiflu and Relenza are proprietary 
preparations of the same neuraminidase inhibitor oseltamivir. In fact 
Tamiflu is the proprietary name for oseltamivir, as stated, but 
Relenza is the proprietary name for a different neuraminidase 
inhibitor called zanamivir. ProMED-mail regrets propagating this 
error.

Nicholas Bennett has provided some useful additional information and 
guidance regarding the use of these 2 neuraminidase inhibitors in 
clinical practice. - Mod.CP]

[see also:
Influenza A (H1N1) - worldwide (65): antivirals in pregnancy 20090616.2224]
...................................cp/mj/lm

*##########################################################*
************************************************************
ProMED-mail makes every effort to  verify  the reports  that
are  posted,  but  the  accuracy  and  completeness  of  the
information,   and  of  any  statements  or  opinions  based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by  ProMED-mail.   ISID
and  its  associated  service  providers  shall not be  held
responsible for errors or omissions or  held liable for  any
damages incurred as a result of use or reliance upon  posted
or archived material.
************************************************************
Become     a    ProMED-mail    Premium     Subscriber     at
<http://www.isid.org/ProMEDMail_Premium.shtml>
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send  all  items  for   posting  to:   promed@promedmail.org

(NOT to  an  individual moderator).  If you do not give your
full name and  affiliation, it  may  not  be  posted.   Send
commands  to  subscribe/unsubscribe,   get  archives,  help,
etc. to: majordomo@promedmail.org.    For assistance  from a
human  being  send  mail  to:   owner-promed@promedmail.org.

############################################################
############################################################

about ISID | membership | programs | publications | resources
14th ICID | site map | ISID home

©2001,2009 International Society for Infectious Diseases
All Rights Reserved.
Read our privacy guidelines.
Use of this web site and related services is governed by the Terms of Service.